PGT Billing: Who Bills What and How to Avoid Lab Claim Conflicts

Preimplantation genetic testing billing is uniquely complex because it involves three entities: the fertility clinic, the embryology lab (in-house or contracted), and the third-party genetics reference laboratory. Each bills for its portion of the service, and CPT codes used at the clinic level overlap with codes that appear on the genetics lab's claim — creating duplicate billing exposure when coordination fails.

What the Clinic Bills

The fertility clinic or its embryology lab bills for embryo biopsy — the procedural component of PGT. CPT 89290 covers embryo biopsy with fewer than 5 embryos; 89291 covers 5 or more embryos. These are the clinic-side PGT codes. The clinic also bills 89258 for embryo cryopreservation if the embryos are frozen during the PGT cycle, which is standard practice since genetic results typically take 7 to 14 days.

What the Genetics Reference Lab Bills

The third-party genetics reference lab bills for the genetic analysis — the array or sequencing component. For PGT-A (aneuploidy testing), the lab typically bills 81228 or 81229 (chromosomal microarray). For PGT-M (monogenic disease testing), billing depends on the specific assay and condition. These analysis codes should appear on the genetics lab's claim — not the clinic's. When clinics bill 81228 alongside 89290 or 89291, payers may flag the claim as duplicating the genetics lab submission.

Common PGT Billing Conflicts

• Clinic bills 81228 or 81229 that the genetics reference lab also submits — creates duplicate claim denial or post-pay recovery.
• Genetics reference lab is out-of-network with the patient's plan, creating an unexpected patient balance that the practice did not disclose.
• Authorization was obtained for the biopsy (89290/89291) but not the genetic analysis — analysis claim denies as unauthorized.
• PGT-M analysis is billed using PGT-A codes — each testing type has distinct code requirements tied to the assay methodology.
• No coordination between clinic and genetics lab on billing responsibility when a biopsy fails or a re-biopsy is performed.

Coordinating Billing Between Clinic and Lab

• Establish a written agreement with your reference genetics lab specifying which entity bills which CPT codes — and what happens in re-biopsy or failed-biopsy scenarios.
• Include the genetics lab's NPI and TIN in the authorization request when payers require both the biopsy and the analysis to be authorized.
• Obtain separate authorizations for the biopsy (clinic) and genetic analysis (reference lab) when the payer requires them.
• Educate patients that they will receive two separate bills for a PGT cycle — one from the clinic and one from the genetics reference lab.
• Audit PGT claims quarterly against genetics lab remittances to identify any overlap in billed codes.

How Payers Adjudicate Overlapping PGT Claims

Payer claim-editing systems flag PGT overlap using a combination of subscriber ID, date of service, CPT, and rendering NPI. When the clinic submits 89290 or 89291 alongside 81228 or 81229, and the reference genetics lab submits the same analysis CPT on a separate claim under its own NPI within the payer's cross-provider duplicate window, the second claim posted typically returns CO-18 (exact duplicate claim or service) or CO-236 (procedure or procedure/modifier combination incompatible with another procedure billed the same day). The order of submission matters: the claim received first is often paid, and the second is denied — which means clinics that submit before the reference lab may be paid initially and then face a post-payment recovery request months later once the payer reconciles both NPIs against a single benefit event.

Benefit accumulation adds a second layer of complexity. The biopsy (89290 or 89291) typically hits the medical-surgical benefit and counts against the fertility-cycle authorization. The genetic analysis (81228 or 81229 for PGT-A) may hit a distinct genetic-testing benefit sub-tier with its own annual cap, its own preauthorization rule, and its own carrier-level review pathway. For self-funded ERISA plans, the two benefits may be administered by different vendors entirely — the medical benefit through the plan's TPA and the genetic-testing benefit through a specialty carve-out. Practices that assume "PGT is covered" based on a single verification call have not verified both benefits.

PGT-A vs. PGT-M vs. PGT-SR: The Analysis Codes Change

The three PGT testing types share the same biopsy CPT codes (89290 or 89291), but the analysis codes on the reference-lab claim diverge sharply. Verifying which testing type is authorized — and which analysis codes the lab will bill — prevents the "auth for PGT-A but claim came in with PGT-M codes" mismatch that denies as CO-197.

• PGT-A (aneuploidy screening): reference lab typically bills 81228 (chromosomal microarray with copy-number variant analysis) or 81229 (with SNP variant analysis). Payer coverage for PGT-A is highly variable — many plans exclude aneuploidy screening as elective.
• PGT-M (monogenic disease testing): reference lab typically bills a molecular pathology code from the Tier 1 (81400 series) or Tier 2 (81401–81408) analyte-specific list when the target gene is on that list, or 81479 (unlisted molecular pathology procedure) when the assay is a custom-designed familial mutation probe. PGT-M frequently also requires a preliminary probe-development phase billed separately by the lab.
• PGT-SR (structural rearrangement): reference lab may bill 81228 or 81229 for the microarray component, plus a custom-probe or interpretive code depending on the arrangement type (reciprocal translocation, Robertsonian translocation, inversion). Reciprocal-translocation PGT-SR is generally the most codable-complex scenario.
• Dx-code pairing changes by testing type. PGT-A most commonly pairs with advanced maternal age (Z31.83 with the patient's age documented) or recurrent pregnancy loss (N96, O26.20–O26.23). PGT-M pairs with the specific genetic disorder ICD-10 code and Z31.430 (encounter of female for testing for genetic disease carrier status) or Z31.440 (encounter of male). Wrong dx-CPT pairing denies as CO-11.

Reading PGT Claim Denials by CARC Code

• CO-18 (exact duplicate claim/service) — the clinic and the reference lab both submitted the analysis CPT. Fix: file a corrected claim removing the analysis code from the clinic claim; leave the reference-lab claim intact.
• CO-197 (precertification, authorization, notification, or pre-treatment absent) — auth was obtained for the biopsy but not the genetic analysis, or auth was obtained for PGT-A but the reference lab submitted PGT-M codes. Recovery is a retro-auth request or a corrected claim to the correct testing type; some payers require an appeal with the original medical-necessity documentation.
• CO-236 (procedure or procedure/modifier combination incompatible) — same-day 89290 and 81228 submitted on the same clinic claim without a supporting modifier, or the clinic and lab claims land on the same DOS without proper coordination. Corrected claim typically resolves.
• CO-11 (diagnosis inconsistent with procedure) — PGT-M billed with a general infertility dx (N97.x, Z31.83) rather than the specific genetic-carrier or affected-family-member dx the payer's coverage policy requires. Corrected claim with the specific dx code and, when available, a supporting genetic-counseling note.
• CO-97 (benefit included in another service) — payer bundled the analysis into the biopsy allowable, or vice versa. Verify the payer's PGT-specific coverage policy before appealing; if the policy explicitly separates the two, appeal with the policy citation.
• PR-96 (non-covered charge) — the payer covers PGT-M for a documented familial monogenic disease but excludes PGT-A as elective aneuploidy screening; or the plan carves out all PGT to a genetic-testing exclusion. Confirm plan-language exclusion vs. medical-policy denial; the latter is appealable, the former is not.
• PR-119 (benefit maximum reached) — the plan's annual genetic-testing dollar or unit cap has been exhausted by prior claims in the plan year. Patient balance-billable up to plan-allowable minus prior-utilization.

Documentation Each Entity Keeps for Audit Defense

PGT claims draw post-payment recovery reviews more often than most fertility procedures because the cross-provider duplicate exposure is well-known to payer audit units. The defense against a recovery request is documentation that proves each entity billed only what it actually performed — and that the two entities did not overlap.

• Clinic keeps: the PGT indication documentation (age, prior-loss history, known familial mutation, referring genetic-counselor note); the operative note for the biopsy including the number of embryos biopsied and each embryo's identifier; chain-of-custody documentation for the biopsied cells shipped to the reference lab; the authorization approvals for both the biopsy and (where separately obtained) the analysis; and the patient consent for genetic testing.
• Reference genetics lab keeps: the assay methodology documentation, quality-control records for the run, the interpretive report signed by a board-certified geneticist, and the CPT codes submitted with matching NPI and TIN.
• Both parties keep: the written coordination agreement defining which CPT codes each entity will submit, how re-biopsy and failed-biopsy scenarios are handled billing-wise, and the escalation path when a duplicate denial surfaces.
• Payer verification log: the coverage-verification call reference number, the representative name, the date, and the specific benefit tiers verified (medical-surgical, genetic-testing, and — for ERISA carve-outs — the specialty vendor administering the genetic-testing benefit).

When the Biopsy Fails or Requires Re-Biopsy

Not every biopsy yields analyzable material. A failed biopsy — insufficient cells recovered, cells lost in transport, or analysis technically unsuccessful at the reference lab — creates a coordinated-billing question that the written coordination agreement should already answer. When cells never reach the reference lab in analyzable condition, the reference lab typically does not submit an analysis claim; the clinic may still bill 89290 or 89291 for the performed biopsy, though some payers apply modifier -53 (discontinued procedure) when the intended downstream service (analysis) did not occur.

Re-biopsy of the same embryo is a distinct scenario. Some payers pay only one biopsy per retrieval regardless of the number of embryos re-biopsied, denying subsequent 89290 or 89291 claims as duplicative under the same retrieval-cycle authorization. Medical-necessity narrative — documenting why the original biopsy did not yield an analyzable result and why re-biopsy was clinically warranted — supports an appeal. When the reference lab reruns the analysis on a re-biopsied sample, whether the analysis code is billed a second time depends on the lab's own policy and the payer's coverage language; the coordination agreement should specify who bears the cost of a re-run when the initial analysis fails at the lab rather than at the clinic.